Zosano Pharma Corporation is a biopharmaceutical company that specializes in developing innovative products for patients who have limited access to existing therapies. Their transdermal microneedle system technology is designed to deliver approved molecules quickly and safely to patients through titanium microneedles coated with medication. Their lead product candidate is Qtrypta™ (M207), a proprietary formulation of zolmitriptan that is delivered via their transdermal microneedle system technology for acute migraine treatments.